MetaCap

Jyong Biotech (MENS) vs OnKure Therapeutics (OKUR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OnKure Therapeutics (OKUR) has outperformed Jyong Biotech (MENS) over the past year, gaining 4.7% versus a loss of 95.3%. OnKure Therapeutics is the larger company by market cap ($111.2 million vs $110.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MENS-95.28%OKUR+4.65%
+114%+4%-105%
Nov 21, 20251 yearNov 20, 2026
MENS-81.90%OKUR+13.92%
+759%+319%-122%
Jun 16, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MENS versus OKUR key metrics
MetricMENSOKUR
Share price$1.45$2.70
Market cap$110.24M$111.21M
1-day change-17.14%-2.17%
YTD return-63.29%-6.90%
1-year return-95.28%+4.65%
5-year return—-96.16%
EPS (TTM)$-0.06$-2.26
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-4.67M$-59.52M
52-week high$38.88$5.38
52-week low$1.43$2.01
Distance from 52-week high-96.27%-49.81%
Analyst consensus—none
Avg. price target upside—+464.81%
Average volume44.23K335.78K
Shares outstanding74.23M40.50M
Employees2745
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OKUR has outperformed MENS by 99.9 percentage points over the past year.

About Jyong Biotech

MENS stock →

Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees

About OnKure Therapeutics

OKUR stock →

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees

MENS vs OKUR FAQ

Which is bigger, Jyong Biotech or OnKure Therapeutics?

OnKure Therapeutics (OKUR) is larger, with a market capitalization of $111.21M compared with $110.24M for Jyong Biotech (MENS).

Which stock has performed better over the past year, MENS or OKUR?

OKUR returned +4.65% over the past 12 months, compared with -95.28% for MENS (price return, excluding dividends). Past performance does not predict future results.

Are Jyong Biotech and OnKure Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons